- Home
- HCM vs IMAX Comparison
HCM vs IMAX Comparison
Compare HCM & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HCM | IMAX |
|---|---|---|
| Founded | 2000 | 1967 |
| Country | Hong Kong | Canada |
| Employees | 1796 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | N/A | 1997 |
Fundamental Metrics
Financial Performance| Metric | HCM | IMAX |
|---|---|---|
| Price | $11.01 | $43.38 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $13.75 | ★ $44.50 |
| AVG Volume (30 Days) | 50.9K | ★ 1.4M |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ 0.35 |
| Revenue | N/A | ★ $410,212,000.00 |
| Revenue This Year | $20.60 | $9.79 |
| Revenue Next Year | $15.62 | $7.51 |
| P/E Ratio | ★ $5.49 | $628.00 |
| Revenue Growth | N/A | ★ 16.47 |
| 52 Week Low | $9.77 | $24.20 |
| 52 Week High | $19.50 | $45.52 |
Technical Indicators
Market Signals| Indicator | HCM | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 47.58 | 63.02 |
| Support Level | $10.83 | $32.93 |
| Resistance Level | $11.80 | $45.52 |
| Average True Range (ATR) | 0.23 | 1.68 |
| MACD | 0.01 | 0.44 |
| Stochastic Oscillator | 16.67 | 69.74 |
Price Performance
Historical ComparisonAbout HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.